Scientists Achieve 90% Effective Malaria Vaccine in Landmark Trial
A new malaria vaccine developed by Oxford researchers shows 90% efficacy in children, potentially saving hundreds of thousands of lives annually.
By Good News Hero Team
In a landmark achievement for global health, researchers at the Oxford Vaccine Group have announced results from a Phase III trial showing their R21/Matrix-M malaria vaccine achieves 90% efficacy in young children in sub-Saharan Africa.
Malaria kills an estimated 600,000 people each year, the vast majority of them children under five in Africa. This new vaccine, developed in partnership with the Serum Institute of India, represents a potential game-changer.
"This is the result decades of work have been pointing toward," said Professor Adrian Hill, Director of the Jenner Institute. "A malaria vaccine that can protect children at this level of efficacy means we can finally envision a world where malaria is a manageable disease."
A new malaria vaccine developed by Oxford researchers shows 90% efficacy in children, potentially saving hundreds of thousands of lives annually.
The vaccine is already being scaled for manufacture. The Serum Institute has committed to producing 100 million doses per year, with pricing designed to make it accessible in the lowest-income countries.
WHO is expected to approve the vaccine for broader rollout later this year, with UNICEF and Gavi positioned to fund distribution in the 15 countries with the highest malaria burden.
